Ahi Evran Medical Journal (Aug 2023)

Survival and Stage in Lung Cancer

  • Kubilay İNAN,
  • Merve ŞENGÜL İNAN,
  • İlknur AYTEKİN ÇELİK,
  • Ozgur Omer YİLDİZ,
  • Nurettin KARAOGLANOGLU

DOI
https://doi.org/10.46332/aemj.1183432
Journal volume & issue
Vol. 7, no. 2
pp. 219 – 224

Abstract

Read online

Purpose: Lung cancer is the leading cause of cancer death worldwide. Although the 5-year survival rates of for non-small cell lung carcinoma (NSCLC) ranges from 20% to 70%. The present study investigates the rates of early recurrence in a total of 83 patients operated for NSCLC and presents the related findings in reference to the data available in the literature. Materials and Methods: Patients who underwent lung resection for malignancy between March 2019 and September 2021 were retrospectively examined. The patient data, including age, gender, presence of preoperative chemotherapy administration, opera-tions performed, operation dates, pathology results, postoperative staging, survival, and relapses, were documented. Results: A total of 83 patients who underwent lung resection for malignancy between March 2019 and September 2021 were examined. The patients had a median age of 62 years. Of the total number of patients four patients developed recurrence and 79 continued their follow-up without any recurrence. Of the patients who underwent lung resection, eight (9.6%) patients died within the first postoperative 2-year period. The mean survival period of these eight patients was 14.6 months (7–20 months). Conclusion: Although various parameters, such as age, gender, pathological type, and location of the tumor are examined and compared, according to the available data on the long-term survival of surgical patients, it is known that the only parameter that affects survival is the pathological stage of the patient.

Keywords